ClariVest Asset Management’s ImmunityBio IBRX Stock Holding History

ClariVest Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-89,642	Closed	-$454K	–	745
2022 Q4	$454K	Sell	89,642 -266	-0.3%	-$1.46K	0.02%	391
2022 Q3	$447K	Sell	89,908 -243	-0.3%	-$1.11K	0.02%	374
2022 Q2	$335K	Buy	90,151 +36,424	+68%	+$146K	0.01%	421
2022 Q1	$302K	Buy	53,727 +14,666	+38%	+$90K	0.01%	438
2021 Q4	$237K	Sell	39,061 -167,271	-81%	-$1.26M	0.01%	474
2021 Q3	$2.01M	Sell	206,332 -10,093	-5%	-$111K	0.07%	233
2021 Q2	$3.09M	Buy	+216,425	New	+$3.58M	0.1%	178

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ClariVest Asset Management's IBRX Position: Q1 2023 in Review

ClariVest Asset Management sold out of ImmunityBio (IBRX) in Q1 2023, closing a stake of 89,642 shares — an estimated $454K sold.

ClariVest Asset Management first reported a position in IBRX in Q2 2021 and held it in 7 quarters. The position peaked at $3.09M in Q2 2021. 146 funds tracked by Wall St. Rank hold IBRX as of Q1 2023.

ClariVest Asset Management reported no remaining ImmunityBio position as of Q1 2023 after selling out during the quarter.
ClariVest Asset Management sold 89,642 ImmunityBio shares in Q1 2023, an estimated $454K.
ClariVest Asset Management first reported a position in ImmunityBio in Q2 2021 and held it in 7 quarters.
ClariVest Asset Management's ImmunityBio position peaked at $3.09M in Q2 2021.
146 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2023.

Based on ClariVest Asset Management's 13F filing for Q1 2023, filed 8 May 2023.